The bull case is that GLP-1 becomes a chronic cardiometabolic platform, not just an obesity drug class. If outcomes data keeps expanding, the market may still underestimate durability.
♥ 0 Thanks from members
Peer Perspective on GLP-1, Obesity & Metabolic Health
Posted 6/15/2026